# Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer

> **NCT05928312** · NA · NOT_YET_RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 72 (estimated)

## Conditions studied

- Advanced Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib Combined With Chemotherapy

## Key facts

- **NCT ID:** NCT05928312
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-08-28
- **Primary completion:** 2025-06-28
- **Final completion:** 2026-06-01
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05928312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05928312, "Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05928312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*